Prilosec OTC Name Will Create Consumer Confusion With Rx Drugs – Petition
This article was originally published in The Tan Sheet
Executive Summary
FDA should require that Prilosec OTC be sold under a different brand name to "reduce the risk of consumer confusion" resulting from extensive direct-to-consumer advertising for the Rx version of the drug, an Aug. 12 citizen petition says
You may also be interested in...
Prilosec OTC Forced Name Change Rejected As FDA Clears Pending Petitions
A lack of data supporting consumer confusion claims between nonprescription Prilosec and the eponymous Rx version is cited by FDA in a letter denying a citizen petition. The petitioner sought an agency-mandated name change
OTC Prilosec Name Derivative Has Precedent In Other Rx Heartburn Switches
FDA has set multiple precedents of switching Rx heartburn remedies over-the-counter while permitting the same trade name for both versions, and should not force a name change for Prilosec OTC, Procter & Gamble says in recent comments to FDA
Prilosec OTC Patent Extension Request “Compels” Name Change – Mylan
AstraZeneca's efforts to extend a patent for Prilosec OTC bolster the case for mandating a name change for the nonprescription product, Mylan says in Oct. 29 comments to FDA